Inspire Medical Systems(NYSE) INSP

Inspire Medical Systems, Inc. makes a device to help people sleep. It treats obstructive sleep apnea, a condition where the airway blocks during sleep, for certain patients. The system helps those who cannot use standard breathing masks.

Solving Sleep Problems

• Inspire System: Neurostimulation technology that uses mild pulses to keep airways open; includes the Inspire IV and newer Inspire V models.
• U.S. Sales: Network of 280 territories selling to hospitals and medical centers; generated 94.5% of revenue for the six-month period ended June 30, 2026.
• International Sales: Global operations focused on markets in Europe and Japan; accounted for 5.5% of revenue during the first half of 2026.

Streamlining for the Future

• Announced Project Horizon on Aug. 3, 2026, to optimize the supply chain and streamline the organization.
• Restructured the sales model to include 301 field clinical representatives to provide technical support as of June 30, 2026.
• Navigated new Medicare requirements in six pilot states that began requiring prior authorization in mid-January 2026.

How the Technology Works

The system uses a closed-loop design to monitor breathing patterns and deliver stimulation to the hypoglossal nerve, which moves the tongue to keep the airway open. This approach provides an alternative for patients with moderate to severe obstructive sleep apnea who do not find relief from traditional treatments.

Key Financial Data

• Revenue was $200.6 million in the three months ended June 30, 2026, down 7.6% year over year.
• Gross margin reached 86.0% for the six-month period ended June 30, 2026, up from 84.4% in the prior year period.
• Net loss was $11.0 million for the six-month period ended June 30, 2026.
• Cash provided by operating activities reached $36.1 million during the first half of 2026.
• Market capitalization was $1.3 billion as of the second quarter of 2026.

A Shifting Business Model

Inspire is transitioning from a high-growth startup to an efficient manufacturer through its Project Horizon initiative. The company is currently managing changing insurance codes and the rising popularity of weight-loss drugs to maintain its position in the sleep apnea market.